Susanne Doblecki-Lewis1, Albert Liu, Daniel Feaster, Stephanie E Cohen, Gabriel Cardenas, Oliver Bacon, Erin Andrew, Michael A Kolber. 1. *Department of Medicine, Division of Infectious Diseases, University of Miami Miller School of Medicine, Miami, FL; †Department of Medicine, University of California; Bridge HIV, San Francisco Department of Public Health, San Francisco, CA; and ‡Population Health Division, Disease Prevention and Control Branch; Division of Infectious Diseases, University of California San Francisco (UCSF), San Francisco, CA.
Abstract
BACKGROUND: Pre-exposure prophylaxis (PrEP) for prevention of HIV infection has demonstrated efficacy in randomized controlled trials and in demonstration projects. For PrEP implementation to result in significant reductions in HIV incidence for men who have sex with men in the United States, sufficient access to PrEP care and continued engagement outside of demonstration projects is required. METHODS: We report the results of a follow-up survey of 173 former participants from the Miami and San Francisco sites of the US PrEP Demo Project, administered 4-6 months after study completion. RESULTS: Survey respondents continued to frequently access medical care and had a high incidence of sexually transmitted infections after completion of the Demo Project, indicating ongoing sexual risk behavior. Interest in continuing PrEP was high with 70.8% indicating that they were "very interested" in continuing PrEP. Among respondents, 39.9% reported continuation of PrEP after completion of the Demo Project, largely through their primary care providers and frequently at low or no cost. Variability in access and engagement was seen, with participants from the San Francisco site, those with medical insurance, and those with a primary care provider at the end of the Demo Project more likely to successfully obtain PrEP medication. Two respondents reported HIV seroconversion in the period between study completion and the follow-up survey. CONCLUSIONS: Additional effort to increase equitable access to PrEP outside of demonstration projects is needed to realize the potential impact of this evidence-based prevention intervention.
BACKGROUND: Pre-exposure prophylaxis (PrEP) for prevention of HIV infection has demonstrated efficacy in randomized controlled trials and in demonstration projects. For PrEP implementation to result in significant reductions in HIV incidence for men who have sex with men in the United States, sufficient access to PrEP care and continued engagement outside of demonstration projects is required. METHODS: We report the results of a follow-up survey of 173 former participants from the Miami and San Francisco sites of the US PrEP Demo Project, administered 4-6 months after study completion. RESULTS: Survey respondents continued to frequently access medical care and had a high incidence of sexually transmitted infections after completion of the Demo Project, indicating ongoing sexual risk behavior. Interest in continuing PrEP was high with 70.8% indicating that they were "very interested" in continuing PrEP. Among respondents, 39.9% reported continuation of PrEP after completion of the Demo Project, largely through their primary care providers and frequently at low or no cost. Variability in access and engagement was seen, with participants from the San Francisco site, those with medical insurance, and those with a primary care provider at the end of the Demo Project more likely to successfully obtain PrEP medication. Two respondents reported HIV seroconversion in the period between study completion and the follow-up survey. CONCLUSIONS: Additional effort to increase equitable access to PrEP outside of demonstration projects is needed to realize the potential impact of this evidence-based prevention intervention.
Authors: Robert M Grant; Peter L Anderson; Vanessa McMahan; Albert Liu; K Rivet Amico; Megha Mehrotra; Sybil Hosek; Carlos Mosquera; Martin Casapia; Orlando Montoya; Susan Buchbinder; Valdilea G Veloso; Kenneth Mayer; Suwat Chariyalertsak; Linda-Gail Bekker; Esper G Kallas; Mauro Schechter; Juan Guanira; Lane Bushman; David N Burns; James F Rooney; David V Glidden Journal: Lancet Infect Dis Date: 2014-07-22 Impact factor: 25.071
Authors: Sheena McCormack; David T Dunn; Monica Desai; David I Dolling; Mitzy Gafos; Richard Gilson; Ann K Sullivan; Amanda Clarke; Iain Reeves; Gabriel Schembri; Nicola Mackie; Christine Bowman; Charles J Lacey; Vanessa Apea; Michael Brady; Julie Fox; Stephen Taylor; Simone Antonucci; Saye H Khoo; James Rooney; Anthony Nardone; Martin Fisher; Alan McOwan; Andrew N Phillips; Anne M Johnson; Brian Gazzard; Owen N Gill Journal: Lancet Date: 2015-09-09 Impact factor: 79.321
Authors: Kenneth H Mayer; Philip A Chan; Rupa R Patel; Charlene A Flash; Douglas S Krakower Journal: J Acquir Immune Defic Syndr Date: 2018-02-01 Impact factor: 3.731
Authors: Charlotte-Paige Rolle; Eli S Rosenberg; Aaron J Siegler; Travis H Sanchez; Nicole Luisi; Kevin Weiss; Scott Cutro; Carlos Del Rio; Patrick S Sullivan; Colleen F Kelley Journal: J Acquir Immune Defic Syndr Date: 2017-11-01 Impact factor: 3.731
Authors: Hansel Tookes; Kristiana Yao; Teresa Chueng; Stefani Butts; Ryan Karsner; Maria Duque; Gabriel Cardenas; Daniel J Feaster; Susanne Doblecki-Lewis Journal: Int J STD AIDS Date: 2019-07-08 Impact factor: 1.359
Authors: Rupa R Patel; Douglas A Luke; Enola K Proctor; William G Powderly; Philip A Chan; Kenneth H Mayer; Laura C Harrison; Amar Dhand Journal: LGBT Health Date: 2018-01 Impact factor: 4.151